Scientific Sessions

Heart failure (HF) is a complex clinical syndrome in which the heart is unable to pump sufficient blood to meet the body’s metabolic needs. It often results from conditions such as coronary artery disease, hypertension, or cardiomyopathy that progressively damage the myocardium. Traditionally, management focused on symptom control and slowing disease progression through lifestyle modifications, pharmacological agents, and device-based therapies. However, recent advances have transformed heart failure care, emphasizing early diagnosis, personalized treatment, and cardiac regeneration. Modern imaging techniques, biomarker profiling, and genetic testing now enable clinicians to detect subclinical dysfunction and tailor therapies to individual patients.

Innovative therapies for heart failure include novel drug classes such as angiotensin receptor-neprilysin inhibitors (ARNIs), sodium-glucose cotransporter-2 (SGLT2) inhibitors, and selective cardiac myosin activators that enhance cardiac contractility and efficiency. Mechanical circulatory support devices, like left ventricular assist devices (LVADs), provide life-sustaining support for advanced cases or serve as a bridge to transplantation. Meanwhile, regenerative medicine is exploring the potential of stem cell therapy, tissue engineering, and gene editing to repair or replace damaged myocardium. Cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillators (ICDs) have also improved survival by optimizing heart rhythm and preventing sudden cardiac death. Together, these cutting-edge interventions mark a shift toward precision and regenerative cardiology, offering new hope for patients with heart failure and significantly improving long-term outcomes and quality of life.